Aegis Lifts PT on Ampio Pharma (AMPE) to $16; Financing Overhang Removed
Get Alerts AMPO Hot Sheet
Price: $0.00 --0%
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 8 | New: 10
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 8 | New: 10
Join SI Premium – FREE
Aegis Capital raises its price target on Ampio Pharmaceuticals (Nasdaq: AMPE) from $15 to $16 and maintains its Buy rating.
Analyst Ram Selvaraju noted that Ampio's financing overhang has largely been removed. The company completed a 9.775 million common stock direct offering last month for gross proceeds of $68 milion. The deal also provides the company with support from key long-term institutional investors.
For an analyst ratings summary and ratings history on click here. For more ratings news on click here.
Shares of closed at $ yesterday.
Analyst Ram Selvaraju noted that Ampio's financing overhang has largely been removed. The company completed a 9.775 million common stock direct offering last month for gross proceeds of $68 milion. The deal also provides the company with support from key long-term institutional investors.
Given the approaching clinical data catalysts of top-line results from the Phase 3 STEP trial of Ampion™ in knee osteoarthrtisis and the Phase 2b trial of Optina™ in diabetic macular edema (DME), we believe that the shares are likely to appreciate substantially over the course of the remainder of 2014 and beyond,the analyst said.
For an analyst ratings summary and ratings history on click here. For more ratings news on click here.
Shares of closed at $ yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPS (UPS) PT Raised to $157 at Oppenheimer
- Incyte (INCY) PT Lowered to $84 at Oppenheimer
- General Motors (GM) PT Raised to $55 at Wedbush
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!